Evaluation of a Patient-Reported Symptom Index for NMIBC
Purpose
This project will develop and evaluate a patient-reported symptom index to assess the impact of treatment for non-muscle invasive bladder cancer on patient burden, toxicity, symptoms and side effects. The symptom index will provide a method for assessing treatments from the patient's perspective; help healthcare professionals make better informed treatment decisions, and provide a method to be able to effectively evaluate treatments for non-muscle invasive bladder cancer.
Condition
- Superficial Bladder Cancer
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- diagnosed NMIBC - Adult (>18yrs) - able to read and understand English - undergoing active treatment (i.e. one week after tumour resection or intravesical therapy) or completed final treatment for NMIBC within the last week
Exclusion Criteria
- unconscious or confused - have cognitive impairment - unable to speak, read and/or write in English - diagnosed with muscle invasive disease - unable to provide informed consent Field test 2: Inclusion Criteria: - newly diagnosed NMIBC - Adult (>18yrs) - able to read and understand English - after imaging or flexible cystoscopy, and before active treatment - either before endoscopic resection, or more than 4 weeks since endoscopic resection, but before active/ongoing treatment Exclusion Criteria: - unconscious or confused - have cognitive impairment - unable to speak, read and/or write in English - diagnosed with muscle invasive disease - unable to provide informed consent - currently undergoing active treatment for any bladder cancer, or finished treatment within last 3 years.
Study Design
- Phase
- Study Type
- Observational [Patient Registry]
- Observational Model
- Cohort
- Time Perspective
- Prospective
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
| NMIBC Patient High Risk | Any of the following: T1 tumours CIS (carcinoma in situ) Multiple and recurring and large (>3cm) Ta, G1, G2 tumours (all these conditions must be presented) (Patients requiring intravesical Bacillus Calmette-Guérin (BCG) (immunotherapy), which starts with 6 week induction treatment and continues with maintenance for 1 to 3 years) | |
| NMIBC Patient Intermediate Risk | All cases between High and Low Risk (Patients requiring intravesical therapy which lasts between 6 weeks to 3 years) | |
| NMIBC Patient Low Risk | Primary, solitary, Ta, LG/G1, <3cm, no CIS (Patients receiving frequent cystoscopies, possible tumour resections and single instillations of postoperative chemotherapy) |
More Details
- Status
- Completed
- Sponsor
- University of Sydney
Study Contact
Detailed Description
The overarching aim of this research is to develop and evaluate a patient-reported Symptom Index (SI) for individuals with NMIBC (the NMIBC-SI) that is acceptable to patients, reliable, valid and responsive, and fit for purpose in clinical trials and clinical practice. Specific clinical aims: - Assess and compare key Patient-Reported Outcomes (PROs) across the full range of contemporary treatments for NMIBC, and over the disease trajectory including acute treatment and 1year survivorship; - Compare PROs between patients with low, intermediate, and high risk NMIBC. In field test 1, 200 participants will complete one questionnaire either in hard copy (pencil and paper) or online, at a time that is convenient for the participant. The questionnaire may take up to 20 minutes to complete. In field test 2, 250 participants will complete quality of life questionnaires at four different time points; 1) before tumour resection, 2) 1 week after resection, 3) 8 weeks after resection, and 4) 1 year after resection. The questionnaires can be completed in the clinic or at home, either in hard copy (pencil and paper) or online, at a time that is convenient for the participant but still within the relevant time point. The questionnaires may take up to 30 minutes to complete.